We characterized 59 hematopoietic tumors using an immunohistochemistry (IHC) panel comprising the markers B220 (specific for B cells), CD3 (T cells), myeloperoxidase (myeloid cells), and CD138 (plasma cells). Here, PTPRC is linked to hematopoietic and lymphoid cell neoplasm.